Search Results - "Milano, Randy J"

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer by Faber, Anthony C., Farago, Anna F., Costa, Carlotta, Dastur, Anahita, Gomez-Caraballo, Maria, Robbins, Rebecca, Wagner, Bethany L., Rideout, William M., Jakubik, Charles T., Ham, Jungoh, Edelman, Elena J., Ebi, Hiromichi, Yeo, Alan T., Hata, Aaron N., Song, Youngchul, Patel, Neha U., March, Ryan J., Tam, Ah Ting, Milano, Randy J., Boisvert, Jessica L., Hicks, Mark A., Elmiligy, Sarah, Malstrom, Scott E., Rivera, Miguel N., Harada, Hisashi, Windle, Brad E., Ramaswamy, Sridhar, Benes, Cyril H., Jacks, Tyler, Engelman, Jeffrey A.

“…BH3 mimetics such as ABT-263 induce apoptosis in a subset of cancer models. However, these drugs have shown limited clinical efficacy as single agents in…”
Get full text

Systematic identification of genomic markers of drug sensitivity in cancer cells by Garnett, Mathew J., Edelman, Elena J., Heidorn, Sonja J., Greenman, Chris D., Dastur, Anahita, Lau, King Wai, Greninger, Patricia, Thompson, I. Richard, Luo, Xi, Soares, Jorge, Liu, Qingsong, Iorio, Francesco, Surdez, Didier, Chen, Li, Milano, Randy J., Bignell, Graham R., Tam, Ah T., Davies, Helen, Stevenson, Jesse A., Barthorpe, Syd, Lutz, Stephen R., Kogera, Fiona, Lawrence, Karl, McLaren-Douglas, Anne, Mitropoulos, Xeni, Mironenko, Tatiana, Thi, Helen, Richardson, Laura, Zhou, Wenjun, Jewitt, Frances, Zhang, Tinghu, O’Brien, Patrick, Boisvert, Jessica L., Price, Stacey, Hur, Wooyoung, Yang, Wanjuan, Deng, Xianming, Butler, Adam, Choi, Hwan Geun, Chang, Jae Won, Baselga, Jose, Stamenkovic, Ivan, Engelman, Jeffrey A., Sharma, Sreenath V., Delattre, Olivier, Saez-Rodriguez, Julio, Gray, Nathanael S., Settleman, Jeffrey, Futreal, P. Andrew, Haber, Daniel A., Stratton, Michael R., Ramaswamy, Sridhar, McDermott, Ultan, Benes, Cyril H.

“…Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for…”
Get full text

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 by Faber, Anthony C, Coffee, Erin M, Costa, Carlotta, Dastur, Anahita, Ebi, Hiromichi, Hata, Aaron N, Yeo, Alan T, Edelman, Elena J, Song, Youngchul, Tam, Ah Ting, Boisvert, Jessica L, Milano, Randy J, Roper, Jatin, Kodack, David P, Jain, Rakesh K, Corcoran, Ryan B, Rivera, Miguel N, Ramaswamy, Sridhar, Hung, Kenneth E, Benes, Cyril H, Engelman, Jeffrey A

“…Colorectal cancers harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug screen, we have…”
Get more information

Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 by Coffee, Erin M., Faber, Anthony C., Costa, Carlotta, Dastur, Anahita, Ebi, Hiromichi, Hata, Aaron N., Yeo, Alan T., J, Elena, Song, Youngchul, Tam, Ah Ting, Boisvert, Jessica L., Milano, Randy J., Roper, Jatin, Kodack, David P., Jain, Rakesh K., Corcoran, Ryan B., Rivera, Miguel N., Ramaswamy, Sridhar, Hung, Kenneth E., Benes, Cyril H., Engelman, Jeffrey A.

“…Abstract Colorectal cancers (CRCs) harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug…”
Get full text